# Foresite Capital Management VI LLC

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 2013341. Source: https://holderbook.com/funds/2013341-foresite-capital-management-vi-llc/

- Reported value: $642.6M
- Positions: 23
- Weight of the ten largest: 81.5%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| CG ONCOLOGY INC | [CGON](https://holderbook.com/stocks/CGON/) | $168.4M | 2,369,574 | 26.2% | 7 |
| ALUMIS INC | [ALMS](https://holderbook.com/stocks/ALMS/) | $119.5M | 4,247,670 | 18.6% | 7 |
| SEAPORT THERAPEUTICS INC | [SPTX](https://holderbook.com/stocks/SPTX/) | $38.7M | 1,779,521 | 6.0% | 1 |
| DENALI THERAPEUTICS INC | [DNLI](https://holderbook.com/stocks/DNLI/) | $35.9M | 1,396,771 | 5.6% | 4 |
| CELLDEX THERAPEUTICS INC NEW | [CLDX](https://holderbook.com/stocks/CLDX/) | $32.7M | 879,713 | 5.1% | 2 |
| AGIOS PHARMACEUTICALS INC | [AGIO](https://holderbook.com/stocks/AGIO/) | $29.1M | 785,000 | 4.5% | 3 |
| CORVUS PHARMACEUTICALS INC | [CRVS](https://holderbook.com/stocks/CRVS/) | $27.4M | 1,831,233 | 4.3% | 7 |
| PARABILIS MEDICINES INC | [PBLS](https://holderbook.com/stocks/PBLS/) | $27.3M | 999,044 | 4.3% | 1 |
| GH RESEARCH PLC | [GHRS](https://holderbook.com/stocks/GHRS/) | $25.3M | 940,493 | 3.9% | 2 |
| JADE BIOSCIENCES INC | [JBIO](https://holderbook.com/stocks/JBIO/) | $19.7M | 886,667 | 3.1% | 2 |
| HINGE HEALTH INC | [HNGE](https://holderbook.com/stocks/HNGE/) | $18.3M | 220,400 | 2.8% | 5 |
| KYMERA THERAPEUTICS INC | [KYMR](https://holderbook.com/stocks/KYMR/) | $16.8M | 146,332 | 2.6% | 7 |
| ATAIBECKLEY INC | [ATAI](https://holderbook.com/stocks/ATAI/) | $14.5M | 2,750,000 | 2.3% | 2 |
| VERASTEM INC | [VSTM](https://holderbook.com/stocks/VSTM/) | $12.0M | 3,146,631 | 1.9% | 5 |
| BEAM THERAPEUTICS INC | [BEAM](https://holderbook.com/stocks/BEAM/) | $11.3M | 330,000 | 1.8% | 1 |
| MINERVA NEUROSCIENCES INC | [NERV](https://holderbook.com/stocks/NERV/) | $11.0M | 1,985,584 | 1.7% | 2 |
| ARRIVENT BIOPHARMA INC | [AVBP](https://holderbook.com/stocks/AVBP/) | $10.5M | 301,341 | 1.6% | 1 |
| AURA BIOSCIENCES INC | [AURA](https://holderbook.com/stocks/AURA/) | $9.5M | 1,333,334 | 1.5% | 1 |
| CRINETICS PHARMACEUTICALS IN | [CRNX](https://holderbook.com/stocks/CRNX/) | $7.9M | 212,010 | 1.2% | 2 |
| RESEARCH ALLIANCE CORP III | [RACC](https://holderbook.com/stocks/RACC/) | $3.2M | 300,000 | 0.5% | 1 |
| ZURA BIO LTD | [ZURA](https://holderbook.com/stocks/ZURA/) | $2.7M | 450,000 | 0.4% | 2 |
| KAILERA THERAPEUTICS INC | [KLRA](https://holderbook.com/stocks/KLRA/) | $826.1K | 37,500 | 0.1% | 1 |
| DISC MEDICINE INC | [IRON](https://holderbook.com/stocks/IRON/) | $70.9K | 970 | 0.0% | 1 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +16.3% | +14.8% | +1.5% | 88% |
| Q1 2026 | +48.5% | -4.6% | +53.1% | 84% |
| Q4 2025 | +17.7% | +2.4% | +15.3% | 96% |
| Q3 2025 | +57.3% | +7.8% | +49.4% | 100% |
| Q2 2025 | -7.6% | +10.5% | -18.1% | 92% |
| Q1 2025 | -18.7% | -4.6% | -14.1% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $642.6M | 23 |
| Q1 2026 | $460.3M | 17 |
| Q4 2025 | $330.8M | 12 |
| Q3 2025 | $258.9M | 12 |
| Q2 2025 | $177.9M | 20 |
| Q1 2025 | $182.5M | 14 |
| Q4 2024 | $224.4M | 14 |